Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10736896 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(8 years from now) | |
US8420656 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(8 years from now) | |
US9604948 | MERCK SHARP DOHME | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9993476 | MERCK SHARP DOHME | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(8 years from now) | |
US8921377 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(8 years from now) | |
US11439642 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 19, 2026 |
NCE-1 date: 2025-01-19
Market Authorisation Date: 19 January, 2021
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
Dosage: TABLET;ORAL
16
United States
11
European Union
6
Hungary
6
Taiwan, Province of China
6
Japan
6
EA
5
Israel
5
Denmark
5
Australia
5
Slovenia
5
Costa Rica
5
Singapore
5
Croatia
5
Spain
5
Korea, Republic of
5
Poland
5
RS
5
China
5
Ukraine
5
Canada
5
New Zealand
4
Lithuania
4
Hong Kong
4
Cuba
4
Brazil
4
Portugal
4
Dominican Republic
4
Peru
4
Chile
3
South Africa
3
Mexico
3
Morocco
3
Uruguay
3
Malaysia
3
Tunisia
2
Philippines
2
Colombia
2
Argentina
2
Guatemala
2
Cyprus
2
Ecuador
2
ME
1
Turkey
1
Jordan
1
Norway
1
AP
1
Germany
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic